Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170885405> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2170885405 endingPage "e177" @default.
- W2170885405 startingPage "e176" @default.
- W2170885405 abstract "The introduction of tyrosine kinase inhibitors into the clinical management of chronic myeloid leukaemia is one of the most remarkable medical success stories of recent years. 1 Apperley JF Chronic myeloid leukaemia. Lancet. 2015; 385: 1447-1459 Summary Full Text Full Text PDF PubMed Scopus (285) Google Scholar In a very short period of time, these drugs have changed the prognosis of chronic myeloid leukaemia from a median survival of 6–7 years to a chronic condition with a prolonged life expectancy. Previous studies 2 Höglund M Sandin F Hellström K et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013; 122: 1284-1292 Crossref PubMed Scopus (94) Google Scholar have shown that life expectancy in younger patients might be returned to normal and the Article in The Lancet Haematology by Koji Sasaki and colleagues 3 Sasaki K Strom S O'Brien S et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015; (published online April 21.)http://dx.doi.org/10.1016/S2352-3026(15)00048-4 Google Scholar now provides the additional evidence that patients and physicians have eagerly awaited. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trialsIn the era of treatment with tyrosine-kinase inhibitors, patients diagnosed with CML-CP can expect a 5-year survival that is only slightly lower than that of the general population. With access to tyrosine-kinase inhibitors, most patients with chronic myeloid leukaemia could enjoy a near normal life expectancy. Full-Text PDF" @default.
- W2170885405 created "2016-06-24" @default.
- W2170885405 creator A5074115908 @default.
- W2170885405 date "2015-05-01" @default.
- W2170885405 modified "2023-09-27" @default.
- W2170885405 title "CML and tyrosine kinase inhibition: the hope becomes reality" @default.
- W2170885405 cites W1968747503 @default.
- W2170885405 cites W1982588049 @default.
- W2170885405 cites W2018195863 @default.
- W2170885405 cites W2023779399 @default.
- W2170885405 cites W2055190439 @default.
- W2170885405 cites W2079352110 @default.
- W2170885405 cites W2166270808 @default.
- W2170885405 cites W2167325977 @default.
- W2170885405 doi "https://doi.org/10.1016/s2352-3026(15)00072-1" @default.
- W2170885405 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26688089" @default.
- W2170885405 hasPublicationYear "2015" @default.
- W2170885405 type Work @default.
- W2170885405 sameAs 2170885405 @default.
- W2170885405 citedByCount "7" @default.
- W2170885405 countsByYear W21708854052017 @default.
- W2170885405 countsByYear W21708854052019 @default.
- W2170885405 countsByYear W21708854052020 @default.
- W2170885405 countsByYear W21708854052021 @default.
- W2170885405 countsByYear W21708854052022 @default.
- W2170885405 crossrefType "journal-article" @default.
- W2170885405 hasAuthorship W2170885405A5074115908 @default.
- W2170885405 hasConcept C121608353 @default.
- W2170885405 hasConcept C126322002 @default.
- W2170885405 hasConcept C133925201 @default.
- W2170885405 hasConcept C143998085 @default.
- W2170885405 hasConcept C170493617 @default.
- W2170885405 hasConcept C194409129 @default.
- W2170885405 hasConcept C2778820342 @default.
- W2170885405 hasConcept C2908647359 @default.
- W2170885405 hasConcept C2993416501 @default.
- W2170885405 hasConcept C42362537 @default.
- W2170885405 hasConcept C535046627 @default.
- W2170885405 hasConcept C71924100 @default.
- W2170885405 hasConcept C99454951 @default.
- W2170885405 hasConceptScore W2170885405C121608353 @default.
- W2170885405 hasConceptScore W2170885405C126322002 @default.
- W2170885405 hasConceptScore W2170885405C133925201 @default.
- W2170885405 hasConceptScore W2170885405C143998085 @default.
- W2170885405 hasConceptScore W2170885405C170493617 @default.
- W2170885405 hasConceptScore W2170885405C194409129 @default.
- W2170885405 hasConceptScore W2170885405C2778820342 @default.
- W2170885405 hasConceptScore W2170885405C2908647359 @default.
- W2170885405 hasConceptScore W2170885405C2993416501 @default.
- W2170885405 hasConceptScore W2170885405C42362537 @default.
- W2170885405 hasConceptScore W2170885405C535046627 @default.
- W2170885405 hasConceptScore W2170885405C71924100 @default.
- W2170885405 hasConceptScore W2170885405C99454951 @default.
- W2170885405 hasIssue "5" @default.
- W2170885405 hasLocation W21708854051 @default.
- W2170885405 hasLocation W21708854052 @default.
- W2170885405 hasOpenAccess W2170885405 @default.
- W2170885405 hasPrimaryLocation W21708854051 @default.
- W2170885405 hasRelatedWork W1596035396 @default.
- W2170885405 hasRelatedWork W2057759464 @default.
- W2170885405 hasRelatedWork W2071007558 @default.
- W2170885405 hasRelatedWork W2335474100 @default.
- W2170885405 hasRelatedWork W2462114439 @default.
- W2170885405 hasRelatedWork W2752416310 @default.
- W2170885405 hasRelatedWork W2968019162 @default.
- W2170885405 hasRelatedWork W3164356684 @default.
- W2170885405 hasRelatedWork W4287188640 @default.
- W2170885405 hasRelatedWork W4206864902 @default.
- W2170885405 hasVolume "2" @default.
- W2170885405 isParatext "false" @default.
- W2170885405 isRetracted "false" @default.
- W2170885405 magId "2170885405" @default.
- W2170885405 workType "article" @default.